迪普科技(300768.SZ):連續12個月內與齊普生簽訂多份合同 銷售訂單金額累計約4.52億元
格隆匯9月27日丨迪普科技(300768.SZ)公佈,杭州迪普科技股份有限公司及其分公司及全資子公司杭州迪普信息技術有限公司(以下合稱“公司”)連續十二個月內與深圳市齊普生科技股份有限公司及其全資子公司齊普生信息科技南京有限公司(以下合稱“齊普生”)簽訂多份日常經營性合同,合同自雙方蓋章(合同章或公章)後生效,銷售訂單金額(不含税)累計達45154萬元,訂單累計金額超過公司最近一個會計年度經審計主營業務收入50%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.